Previous close | 25.16 |
Open | 25.17 |
Bid | 23.47 x 800 |
Ask | 25.21 x 800 |
Day's range | 24.95 - 25.90 |
52-week range | 13.60 - 63.68 |
Volume | |
Avg. volume | 737,988 |
Market cap | 1.561B |
Beta (5Y monthly) | 0.63 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
SpringWorks' (SWTX) phase III study evaluating its investigational candidate, nirogacestat, in adult patients with progressing desmoid tumors, meets primary and key secondary endpoints.